《共识》中提到："复方口服避孕药（combined oral contraceptives，COC）是目前全球范围广泛使 用的高效避孕方法之一……目前，COC在我国育龄期妇女中的使用率非常低，出于对激素类药物的恐 惧心理，对COC的了解不足或存在偏见，是我国COC使用率甚低的主要原因之一。"这种认知差距，使 得许多女性未能充分利用这类可同时提供避孕与非避孕健康获益（如治疗中度痤疮）的科学方案。 复旦大学附属妇产科医院史颖莉教授说："对于临床诊断明确、治疗方案稳定、需长期药物支持的 慢性病患者，经专业医生评估后可开具长处方。避孕及痤疮治疗均需在医师指导下长期规范用药，一旦 因购药不及时而中断，往往会影响疗效。优思悦®84片装的推出，有助于减少频繁购药和不当停药的情 况，提升患者依从性和用药连续性，为临床实践和患者管理提供了更为便利的选择。" 优思悦®（屈螺酮炔雌醇片Ⅱ）是一种短效口服避孕药，2014年12月份在中国获批上市，是中国首 个采用"24+4"给药模式的复方口服避孕药，24片活性药片（每片含0.02mg炔雌醇和3mg屈螺酮）加4片 无活性药片，适用于女性避孕，及≥14岁、没有口服避孕药已知禁忌的已初潮女 ...

与此同时，《复方口服避孕药临床应用中国专家共识》（以下简称《共识》）解读活动也正式启动，聚 焦疾病长程管理，旨在提升女性对用药依从性在疾病管理中关键作用的认知。 本报讯 （记者袁传玺）1月29日，拜耳原研口服避孕药优思悦 84片装大包装首批药品顺利完成进口通 关，率先在阿里健康首发，该规格于第八届中国国际进口博览会首次亮相，旨在覆盖三个月完整的用药 周期，提升用药的便利性和依从性，更好地契合女性健康长周期管理的实际需求。 《共识》中提到："复方口服避孕药（combined oral contraceptives，COC）是目前全球范围广泛使用的 高效避孕方法之一……目前，COC在我国育龄期妇女中的使用率非常低，出于对激素类药物的恐惧心 理，对COC的了解不足或存在偏见，是我国COC使用率甚低的主要原因之一。"这种认知差距，使得许 多女性未能充分利用这类可同时提供避孕与非避孕健康获益（如治疗中度痤疮）的科学方案。 复旦大学附属妇产科医院史颖莉教授说："对于临床诊断明确、治疗方案稳定、需长期药物支持的慢性 病患者，经专业医生评估后可开具长处方。避孕及痤疮治疗均需在医师指导下长期规范用药，一旦因购 药不及时而中断， ...

CALGARY, Alberta--(BUSINESS WIRE)--Bayer Crop Science today announced an unprecedented $45+ million CAD investment to strengthen Canada's leadership in canola innovation by establishing a cutting-edge canola innovation centre. Located in Winnipeg, Manitoba, the facility will house seed development work for canola, camelina and winter canola, focusing on trait integration, yield trial seed processing and seed quality analysis. "A long-term strategic investment of this scale demonstrates Bayer's. ...

Core Insights - Zacks Premium offers tools for investors to enhance their stock market strategies, including daily updates, research reports, and stock screens [1] - The Zacks Style Scores provide a framework for evaluating stocks based on value, growth, and momentum, aiding investors in selecting securities likely to outperform the market [2] Zacks Style Scores Overview - Stocks are rated A, B, C, D, or F based on their value, growth, and momentum characteristics, with higher scores indicating a better chance of outperforming the market [3] - The Style Scores are categorized into four types: Value Score, Growth Score, Momentum Score, and VGM Score [3][4][5][6] Value Score - The Value Style Score focuses on identifying undervalued stocks using metrics like P/E, PEG, Price/Sales, and Price/Cash Flow [3] Growth Score - The Growth Style Score assesses a company's financial health and future outlook through projected and historical earnings, sales, and cash flow [4] Momentum Score - The Momentum Style Score evaluates trends in stock prices and earnings estimates to identify favorable buying opportunities [5] VGM Score - The VGM Score combines all three Style Scores, providing a comprehensive indicator for investors seeking attractive value, growth, and momentum [6] Zacks Rank Integration - The Zacks Rank utilizes earnings estimate revisions to simplify portfolio building, with 1 (Strong Buy) stocks achieving an average annual return of +23.83% since 1988, significantly outperforming the S&P 500 [7] - There are over 800 stocks rated 1 or 2, making it essential for investors to utilize Style Scores to narrow down choices [8] Investment Strategy - For optimal returns, investors should focus on stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B, while 3 ranked stocks should also have high Style Scores to maximize upside potential [9][10] Company Spotlight: Bayer Aktiengesellschaft - Bayer AG, headquartered in Leverkusen, Germany, is rated 2 (Buy) on the Zacks Rank with a VGM Score of A and a Value Style Score of A, indicating strong valuation metrics [11] - The company has seen two analysts raise their earnings estimates for fiscal 2025, with the Zacks Consensus Estimate increasing by $0.10 to $1.43 per share and an average earnings surprise of +18.5% [12]

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the "long context," investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.Even ...

Company Overview - Arcellx, Inc. (ACLX) is part of the Medical group, which consists of 932 companies and currently ranks 8 within the Zacks Sector Rank [2] - The company belongs to the Medical - Biomedical and Genetics industry, which includes 453 companies and is ranked 93 in the Zacks Industry Rank [6] Performance Metrics - Year-to-date, Arcellx, Inc. has returned approximately 10.7%, outperforming the average gain of 6% for Medical stocks [4] - The Zacks Consensus Estimate for ACLX's full-year earnings has increased by 1.2% over the past quarter, indicating improved analyst sentiment [4] Comparison with Peers - Bayer Aktiengesellschaft (BAYRY), another Medical stock, has outperformed the sector with a year-to-date return of 15.6% and a Zacks Rank of 1 (Strong Buy) [5] - The Large Cap Pharmaceuticals industry, which includes Bayer, has gained 19.8% since the beginning of the year, while Arcellx, Inc. is slightly underperforming its industry group [6][7]

Core Viewpoint - Bayer AG's shares increased by 6.41% following the announcement that the Supreme Court will review the Durnell Roundup case, which is significant for the company's ongoing litigation related to its glyphosate-based herbicide Roundup [1][9]. Legal Developments - The Supreme Court's review will address a split among federal circuit courts regarding federal preemption, a key issue in the Roundup litigation [2][9]. - The Solicitor General has supported the review, emphasizing the need to resolve the circuit split and advocating for a ruling in favor of Bayer [3][4]. - The Durnell case resulted in a jury awarding $1.25 million in damages for failure to warn, with Monsanto appealing the verdict [6]. Litigation Status - As of October 15, 2025, Bayer has resolved approximately 132,000 of nearly 197,000 claims related to glyphosate, with a reserve of $7.6 billion set aside for ongoing litigation [10][9]. - Bayer has experienced a mix of outcomes in 28 concluded Roundup-related trials, securing favorable results in 17 cases [8]. Financial Performance - Bayer's shares have surged by 138.5% over the past year, significantly outperforming the industry average of 24.1%, driven by new drug approvals and improved performance in its Crop Science business [11]. - The company has seen strong sales from new products like prostate cancer drug Nubeqa and kidney disease drug Kerendia, which have offset declines in sales from Xarelto [12]. Drug Approvals - Bayer recently received FDA approval for elinzanetant for menopause-related symptoms and accelerated approval for Hyrnuo for lung cancer treatment, which are expected to enhance sales [15][16]. - The expansion of key drugs and the approval of additional products are anticipated to further boost sales in Bayer's pharmaceutical division [18].

Core Insights - Bayer and Vanderbilt University Medical Center (VUMC) have entered a strategic five-year collaboration agreement to advance innovative therapies from target identification through Investigational New Drug (IND) application [1] - The collaboration will focus on all indications currently pursued by Bayer, with an initial emphasis on cardiovascular and kidney diseases, which are areas with significant unmet medical needs [1] Company Overview - Bayer is engaging in a partnership with VUMC to enhance its research and development capabilities in the field of innovative therapies [1] - The collaboration aims to streamline the process from identifying therapeutic targets to applying for IND, indicating a comprehensive approach to drug development [1] Industry Context - The focus on cardiovascular and kidney diseases highlights the ongoing challenges and unmet medical needs within these therapeutic areas, suggesting potential growth opportunities for companies involved in related research and development [1]

欧洲的现实主义转向给国际格局带来了新的变数。欧美关系的震荡，客观上对中国有利。但欧洲的政客传统上并非简单站队，而是更多地根据利益做出选 择。默茨此行的目的，除了测试中国在当前国际格局中的地位外，也是希望为欧洲争取更多的战略空间。只要美国国内局势有所缓和，欧美关系随时可能回 暖，这也是欧洲敢于短暂强硬的原因之一。美国面临的压力不小，临近的中期选举、不断消耗资源的俄乌战争和中东问题，都让特朗普不得不顾及到国内政 治的压力，这也是为何欧洲敢在这一时刻展现出更为独立的姿态。然而，历史经验告诉我们，欧洲的战略自主性从来不牢固，情绪和局势的变化很可能导致 其重新调整与美国的关系。中国在面对这些欧洲政要的访华时，必须稳住节奏，深化合作的同时，明确底线，不可以将这些接近的阶段误认为是长期站队的 标志。德国此行的决定，实际上是基于对现实的理性判断。世界已经进入一个更加现实的时代，过去的盟友关系不再牢不可破，规则随时有可能被改写。谁 能提供确定性，谁就能成为国际格局中的核心力量。德国经济的高度依赖外贸，这一次转向东方，正是理性选择的体现。而加拿大调整对华政策的做法，或 许将成为其他欧洲国家跟进的先例。 与此同时，德国总理默茨的访 ...

Core Viewpoint - Bayer's stock price surged significantly following the U.S. Supreme Court's decision to hear the company's appeal in the Roundup litigation, presenting a potential opportunity to limit its multi-billion dollar legal liabilities related to the herbicide's alleged carcinogenic effects [1][2]. Group 1: Legal Developments - The U.S. Supreme Court agreed to review Bayer's challenge against a $1.25 million jury verdict from Missouri, which found that Bayer failed to warn about the potential cancer risks of Roundup [1]. - Legal experts anticipate that oral arguments will be scheduled for spring 2026, with a ruling expected by mid-2026 [1]. - If Bayer wins, it could lead to the dismissal of thousands of similar "failure to warn" lawsuits across the U.S., significantly reducing its financial risk [1][2]. Group 2: Market Reactions - Bayer's stock rose by 7.5% to €44.42 in European trading, marking its largest single-day increase since early December, and its cumulative gain over the past 12 months is approaching 100% [1]. - In the U.S. over-the-counter market, Bayer's American Depositary Receipts (ADRs) increased by over 6.4% to $12.95 [1]. - Analysts are optimistic about the Supreme Court's decision as a significant step towards resolving Bayer's long-standing litigation issues, which may enhance its position in settlement negotiations [2]. Group 3: Business Outlook - Bayer's core defense in the litigation is based on the approval of its product labeling by the Environmental Protection Agency (EPA), arguing that federal law should take precedence over state-level claims [2]. - Following the court's decision, Bank of America and Morgan Stanley raised their target prices for Bayer, citing reduced litigation risks and a positive outlook for its pharmaceutical business, particularly with upcoming drug launches [2]. - Analysts expect strong sales from new drugs such as Kerendia for kidney disease and Nubeqa for prostate cancer [2].